[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1499
1. Srisomboon J, Kietpeerakool C, Suprasert P, Siriaunkgul S, Khunamornpong S, Prompittayarat W: Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy. Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):225-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy.
  • The objective of this study was undertaken to evaluate the factors affecting residual lesion in women with adenocarcinoma in situ (AIS) on cervical conization specimens.
  • The medical records of women with AIS who had no associated invasive carcinoma after cervical conization and underwent subsequent hysterectomy at Chiang Mai University Hospital were reviewed.
  • Thirteen (28.9%) women presented with AIS on Pap smear.
  • Twenty (44.4%) women had mixed lesions of AIS and squamous intraepithelial lesion on cervical specimens.
  • In conclusion, approximately one-third of women with AIS on cervical conization have residual lesion on subsequent hysterectomy specimens.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Neoplasm, Residual / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Biopsy. Carcinoma in Situ / epidemiology. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Female. Humans. Hysterectomy. Incidence. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / pathology. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696736.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


2. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol; 2007 Feb;20(2):242-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
  • Adenocarcinoma in situ of the uterine cervix remains a diagnostic challenge in a small proportion of cases.
  • This suggests a need for biomarker that may be of help in establishing the diagnosis.
  • The aim of this study was to evaluate the potential of insulin-like growth factor-II mRNA-binding protein 3 and cyclin-dependent kinase inhibitor p16(INK4a) as biomarkers for adenocarcinoma in situ.
  • Forty-four samples of adenocarcinoma in situ from 40 patients and 23 control cases of benign uterine cervix were included in this study.
  • Cytoplasmic immunoreactivity for insulin-like growth factor-II mRNA-binding protein 3 was identified in 41 (93%) adenocarcinoma in situ samples, among which, 29 (71%), 10 (24%), and 2 (5%) samples showed insulin-like growth factor-II mRNA-binding protein 3 positive staining in 50% or more, >5 to <50 and <5% of adenocarcinoma in situ lesional cells, respectively.
  • Immunohistochemical reaction intensity for insulin-like growth factor-II mRNA-binding protein 3 was found to be strong in 34 adenocarcinoma in situ samples, intermediate in five, and weak in two.
  • All 23 control cases were negative for insulin-like growth factor-II mRNA-binding protein 3. p16(INK4a) expression was identified in all of the adenocarcinoma in situ samples with intermediate staining intensity seen in seven samples and strong in the remainder.
  • Our findings demonstrate significant expression of insulin-like growth factor-II mRNA-binding protein 3 and p16(INK4a) in adenocarcinoma in situ as compared to benign endocervical glands, suggesting that expression of these biomarkers may be helpful in the distinction of adenocarcinoma in situ from benign endocervical glands, particularly in difficult borderline cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192788.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


3. van de Nieuwenhof HP, Massuger LF, de Hullu JA, van Ham MA, van Dijck JA, Siebers AG, Bekkers RL: Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. Br J Cancer; 2008 Jan 15;98(1):165-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003.
  • Over the period 1989-2003, the incidence of cervical adenocarcinoma (n=1615) was stable whereas that of cervical adenocarcinoma in situ (n=1884) significantly decreased (P=0.008), mainly caused by adenocarcinoma in situ lesions with a concurrent squamous dysplasia.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] CMAJ. 2001 Apr 17;164(8):1151-2 [11338801.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):314-26 [12352181.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):330-7 [12478680.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):886-90 [12942122.001]
  • [Cites] Obstet Gynecol. 2003 Oct;102(4):765-73 [14551007.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):336-41 [14681940.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1035-44 [14983500.001]
  • [Cites] J Clin Pathol. 1986 Jan;39(1):22-8 [3950029.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Obstet Gynecol. 1995 Jun;85(6):1017-21 [7770247.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):252-8 [9119549.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):166-70 [8995568.001]
  • [Cites] Int J Gynecol Pathol. 1997 Apr;16(2):103-10 [9100062.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):448-52 [9277660.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Obstet Gynecol. 1998 Jun;91(6):969-72 [9611006.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):200-9 [9704619.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):112-7 [10396238.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):159-66 [10487628.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):55-61 [10502426.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1005-9 [15515017.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):376-8 [16012518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):399-403 [16175089.001]
  • [Cites] Acta Obstet Gynecol Scand. 2006;85(1):106-11 [16521689.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):362-7 [17072843.001]
  • [Cites] J Reprod Med. 2000 Aug;45(8):613-5 [10986677.001]
  • (PMID = 18182979.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359688
  •  go-up   go-down


Advertisement
4. Shah SS, Adelson M, Mazur MT: Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases. Int J Gynecol Pathol; 2008 Jul;27(3):453-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases.
  • Adenocarcinoma in situ rarely occurs in vulvar papillary hidradenoma.
  • We encountered 2 cases of adenocarcinoma in situ arising in a papillary hidradenoma of the vulva.
  • On microscopic examination, the tumors showed focal features of benign hidradenoma at the periphery with transitions into areas of increasing cytologic atypia that fulfilled criteria for adenocarcinoma in situ similar to that seen in the breast.
  • Both lesions show areas strongly immunoreactive for mammaglobin and gross cystic disease fluid protein 15 as well as estrogen and progesterone receptor protein in 1 case.
  • The fact that these tumors displayed morphologic and immunohistochemical features that resembled ductal carcinoma in situ of the breast demonstrates the close homology between papillary hidradenoma and breast epithelium.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Carcinoma in Situ / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Disease Progression. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580327.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • Histologically, the excised lesion showed features of tubulopapillary apocrine hidradenoma, with an area showing features of carcinoma in situ.
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Kämmerer PW, Kreft A, Toyoshima T, Al-Nawas B, Klein MO: Misleading initial histological diagnosis of a polymorphous low-grade adenocarcinoma in situ ex pleomorphic adenoma-a case report. Oral Maxillofac Surg; 2009 Jun;13(2):99-103
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misleading initial histological diagnosis of a polymorphous low-grade adenocarcinoma in situ ex pleomorphic adenoma-a case report.
  • INTRODUCTION: Polymorphous low-grade adenocarcinoma (PLGA) are frequent tumours of palatinal minor salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Carcinoma in Situ / pathology. Neoplasms, Multiple Primary / pathology. Palatal Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy / methods. Diagnosis, Differential. Female. Humans. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Dec;118 Suppl:S100-15 [14569817.001]
  • [Cites] Acta Odontol Latinoam. 2007;20(1):23-31 [18046967.001]
  • [Cites] Laryngoscope. 2006 Dec;116(12):2145-9 [17146387.001]
  • [Cites] Head Neck Surg. 1986 Mar-Apr;8(4):268-75 [3017896.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 2008 Jun;109(3):178-82 [18534647.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):457-63 [10349381.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1973 Sep-Oct;82(5):684-90 [4355182.001]
  • [Cites] Minerva Stomatol. 2004 Mar;53(3):111-5 [15107782.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):323-33 [2845326.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Jun;118(6):850-2 [9627248.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):207-19 [10421256.001]
  • [Cites] Otolaryngol Pol. 2002;56(6):737-40 [12577492.001]
  • [Cites] Oral Oncol. 2007 May;43(5):463-70 [16979373.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 Nov;4(6):543-51 [15579019.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):163-9 [18327037.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):379-85 [1617588.001]
  • [Cites] J Laryngol Otol. 1995 Mar;109(3):240-3 [7745345.001]
  • [Cites] Acta Histochem. 2006;108(4):259-64 [16899283.001]
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):641-5 [12167416.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jan;77(1):41-7 [8108096.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):291-5 [10656742.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):935-42 [6692293.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):691-5 [9195625.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1319-28 [11023093.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):134-8 [17288880.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Dec;265(12):1563-6 [18288478.001]
  • [Cites] J Korean Med Sci. 1997 Feb;12(1):63-6 [9142663.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] J Contemp Dent Pract. 2008 Sep 01;9(6):99-107 [18784865.001]
  • [Cites] Chin Med J (Engl). 2008 Oct 5;121(19):1945-52 [19080129.001]
  • (PMID = 19189140.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Roberts JM, Thurloe JK: Comparative sensitivities of ThinPrep and Papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): comparison with HSIL. Cancer; 2007 Dec 25;111(6):482-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative sensitivities of ThinPrep and Papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): comparison with HSIL.
  • BACKGROUND: Despite the historic belief that cytologic screening offers little protection against cervical adenocarcinoma (CAC), there is emerging evidence that, by detecting the precursor lesion, adenocarcinoma in situ (AIS), cervical screening may reduce the incidence of CAC as it has for cervical squamous carcinoma.
  • Because liquid-based cytology is fast replacing the conventional Papanicolaou smear (PS), it is important to establish that it is at least as effective in detecting AIS.
  • METHODS: The authors calculated the sensitivities of PS and ThinPrep (TP) for 100 women with histologic AIS (from 160 PS slides and 60 TP slides), for 94 women with AIS+high-grade squamous intraepithelial lesion (HSIL) (from 151 PS slides and 50 TP slides), and for 558 women with HSIL (from 788 PS slides and 383 TP slides).
  • All smears were taken up to 36 months before the histologic diagnosis.
  • However, when sensitivity was defined as cytologic detection of high-grade disease, there was no difference between any of the categories.
  • For the detection of a high-grade glandular lesion, the presence of a concurrent histologic HSIL was associated with reduced sensitivity for the detection of AIS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Cytodiagnosis / methods. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 17969065.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, Malila N, Nieminen P: Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ; 2010;340:c1804
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
  • MAIN OUTCOME MEASURES: Rate of cervical cancer, cervical intraepithelial neoplasia (CIN) grade III, and adenocarcinoma in situ (as a composite outcome referred to as CIN III+) during 2003-7 through record linkage between files from the screening registry and the national cancer registry.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2008 Apr 2;100(7):492-501 [18364502.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1344-9 [18566992.001]
  • [Cites] BMJ. 2008;337:a1754 [18852164.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1385-94 [19339719.001]
  • [Cites] Lancet Oncol. 2009 Jul;10(7):672-82 [19540162.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):565-71 [18248809.001]
  • [Cites] IARC Sci Publ. 1986;(76):1-315 [3570396.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):559-65 [1911199.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):862-7 [16189520.001]
  • [Cites] BMC Public Health. 2006;6:252 [17042938.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1589-97 [17942872.001]
  • [Cites] Lancet. 2007 Nov 24;370(9601):1764-72 [17919718.001]
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2209-14 [11072206.001]
  • (PMID = 20423964.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN23885553
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Probes; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC3191726
  •  go-up   go-down


9. Akiba Y, Kubushiro K, Fukuchi T, Fujii T, Tsukazaki K, Mukai M, Nozawa S: Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix? J Obstet Gynaecol Res; 2005 Jun;31(3):252-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laser conization adequate for therapeutic excision of adenocarcinoma in situ of the uterine cervix?
  • AIMS: To determine the safety of uterine-preserving operations for adenocarcinoma in situ of the cervix.
  • METHODS: Fifteen cases of adenocarcinoma in situ (AIS) were diagnosed using neodymium:yttrium aluminum garnet (Nd:YAG) laser conization.
  • The accuracy of preconization histology or cytology was evaluated in 15 AIS cases.
  • In these AIS cases, we investigated how far the tumor was located from the squamocolumnar junction (SCJ) and the endocervix.
  • Fourteen cases of the 15 AIS-affected patients were treated using laser conization alone.
  • RESULTS: Precise agreement between preconization diagnosis and conization histology was seen in 46.7% (7/15) of the AIS cases.
  • In 14 of the 15 cases of AIS (93.3%), the tumor was adjacent to the transitional zone, within 3 mm of the SCJ, and in the other case (6.7%), the tumor was between 0 and 5 mm away from the SCJ.
  • None of the 15 patients showed any recurrence of AIS during follow up ranging from 15 to 75 months (43.1 months on average).
  • CONCLUSIONS: Women with AIS who want to preserve their fecundity might be treated with laser conization alone.
  • [MeSH-major] Adenocarcinoma / surgery. Cervix Uteri / surgery. Conization / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916663.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Griffin D, Manuck TA, Hoffman MS: Adenocarcinoma in situ of the cervix in pregnancy. Gynecol Oncol; 2005 May;97(2):662-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the cervix in pregnancy.
  • INTRODUCTION: The number of patients diagnosed with adenocarcinoma in situ of the cervix has increased in the last decade.
  • The number of pregnant patients with this disease can also be expected to increase.
  • CASES: In this report, we describe three patients diagnosed with adenocarcinoma in situ of the cervix during pregnancy.
  • DISCUSSION: The management of adenocarcinoma in situ of the cervix may include procedures which present substantial risks to an ongoing pregnancy and more conservative management may be warranted in many instances.
  • [MeSH-major] Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Female. Humans. Pregnancy


11. Zardo LM, Thuler LC, Zeferino LC, Horta NM, Fonseca Rde C: Performance of the cytologic examination for the diagnosis of endocervical adenocarcinoma in situ: cytologic-histologic correlation in 60 cases. Acta Cytol; 2009 Sep-Oct;53(5):558-64
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance of the cytologic examination for the diagnosis of endocervical adenocarcinoma in situ: cytologic-histologic correlation in 60 cases.
  • OBJECTIVE: To analyze the performance of cytologic examinations for the diagnosis of adenocarcinoma in situ (AIS) through the correlation between the cytologic and histologic findings.
  • STUDY DESIGN: This study included 60 patients followed at the Brazilian National Cancer Institute from November 1998 to December 2007, with the cytopathologic diagnosis of AIS.
  • RESULTS: Histologic study confirmed AIS in 28.3% (17/60) and invasive endocervical adenocarcinoma in 38.3% (23/60) of the cases.
  • In 21.7% (13/60) of the patients, the histologic examination revealed cervical intraepithelial neoplasia (CIN) 2/3 and in 5.0% (3/60) squamous invasive carcinoma; in the remaining 5.0% (3/60) the diagnosis pointed to other neoplasms, and 1.7% (1/60) showed exclusively benign squamous cell lesions.
  • Cytology identified lesions in 98.3% of the patients; 51% was intraepithelial.
  • CONCLUSION: Although cytomorphologic criteria for diagnosis of AIS have been published, there was significant difficulty in interpreting glandular lesions.
  • As knowledge of this diagnosis increases, better performance is expected.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19798884.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Westin MC, Derchain SF, Rabelo-Santos SH, Angelo-Andrade LA, Sarian LO, Oliveira E, Zeferino LC: Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications. Eur J Obstet Gynecol Reprod Biol; 2008 Jul;139(1):79-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications.
  • BACKGROUND: The objective of this study was to evaluate the correlation between the 2001 Bethesda classification of endocervical glandular abnormalities and histological diagnosis.
  • STUDY DESIGN: A series of 155 women with endocervical glandular abnormalities on cervical smears were included: 91 with atypical glandular cells (AGC) not otherwise specified (NOS), 15 with AGC-favor neoplastic (FN); 35 with AGC associated with high-grade squamous intraepithelial lesion (HSIL) as combined diagnosis and 14 with adenocarcinoma in situ (AIS).
  • RESULTS: Histological outcome of squamous neoplasias (CIN 2 or worse) and adenocarcinoma were significantly associated with AGC-FN and AIS, taking as reference AGC-NOS, and more associated with AIS than AGC-FN.
  • Similar associations were observed for histological outcome of adenocarcinoma, but no association was observed for only squamous neoplasia.
  • Histological outcome of CIN2 or worse was strongly associated with AGC when HSIL was also present, but no association was observed with only for adenocarcinoma histological outcome.
  • CONCLUSIONS: AGC-NOS, AGC-FN and AIS cytological diagnosis represent a progressively increasing association with neoplastic diagnosis, due to progressively increasing association with adenocarcinoma.
  • The presence of HSIL associated with AGC represents greater probability of squamous neoplasia but not adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology


13. Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO: Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. Gynecol Oncol; 2007 Nov;107(2):316-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.
  • OBJECTIVES: Cervical adenocarcinoma in situ (AIS) is a precursor of invasive disease that is increasing in incidence primarily among reproductive-age women of low parity.
  • Conization is an alternative to hysterectomy that allows future pregnancy, but has an inherent risk of residual AIS.
  • METHODS: Women diagnosed with cervical AIS who underwent primary fertility-sparing surgery with either loop excision or cold knife conization between 1993 and 2001 were identified at three institutions.
  • Patients 40 years of age and older and those undergoing hysterectomy within 12 months of diagnosis were excluded.
  • No invasive cervical adenocarcinomas were observed during the study interval.
  • CONCLUSION: Fertility-sparing surgery enables women with cervical AIS to achieve pregnancy with minimal risk of developing invasive disease during surveillance.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Fertility. Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Carcinoma in Situ / surgery. Cohort Studies. Female. Humans. Hysterectomy. Medical Records. Parity. Population Surveillance. Pregnancy. Pregnancy Outcome. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689593.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


14. Cohn DE, Morrison CD, Zanagnolo VL, Goist MM, Copeland LJ: Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. Gynecol Oncol; 2005 Jul;98(1):158-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins.
  • BACKGROUND: Cervical adenocarcinoma in situ is often diagnosed in younger women who may wish to preserve the potential for fertility.
  • Given that the rate of recurrent adenocarcinoma in situ is relatively low and the risk of invasive adenocarcinoma is extremely rare, conservative management in this population after a cone biopsy demonstrates negative margins has been accepted as an appropriate management strategy.
  • This case challenges the concept of conservative management of cervical adenocarcinoma in situ.
  • A 1.5-cm lesion was noted at the endocervix, and a punch biopsy revealed adenocarcinoma in situ.
  • A large cold knife cone biopsy confirmed cervical adenocarcinoma in situ with negative margins.
  • Definitive therapy for in situ disease with an extrafascial hysterectomy was performed 12 days after conization, and demonstrated stage IB1 cervical adenocarcinoma.
  • A radical parametrectomy, radical upper vaginectomy, and pelvic lymphadenectomy were without persistent disease.
  • CONCLUSION: Conservative management of cervical adenocarcinoma in situ after a cone biopsy with negative margins does not exclude the possibility of concurrent invasive cervical adenocarcinoma.
  • This case challenges the current balance between risk and benefit associated with the conservative management of cervical adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / pathology. Conization. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913738.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ault KA, Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet; 2007 Jun 2;369(9576):1861-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
  • BACKGROUND: Cervical cancer and its obligate precursors, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), and adenocarcinona in situ (AIS), are caused by oncogenic human papillomavirus (HPV).
  • The primary composite endpoint was the combined incidence of HPV16/18-related CIN2/3, AIS, or cervical cancer.
  • In a second intention-to-treat analysis we noted an 18% reduction (95% CI 7-29) in the overall rate of CIN2/3 or AIS due to any HPV type.
  • [MeSH-major] Adenocarcinoma / prevention & control. Cervical Intraepithelial Neoplasia / prevention & control. Papillomavirus Vaccines

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Sep 22;370(9592):1031; author reply 1032-3 [17889237.001]
  • [CommentIn] Lancet. 2007 Jun 2;369(9576):1837-9 [17544748.001]
  • [CommentIn] Evid Based Med. 2007 Dec;12(6):168 [18063728.001]
  • [CommentIn] Lancet. 2007 Sep 22;370(9592):1031-2; author reply 1032-3 [17889236.001]
  • (PMID = 17544766.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00092521/ NCT00092534/ NCT00365378/ NCT00365716
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


16. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2009) and other non-adenocarcinoma tumors.
  • We also observed Id1 exp. in tumor in situ areas near the invasive carcinoma in 16 out of 20 pts expressing Id1 in the primary tumor.
  • Id1 exp. in tumor in situ areas suggests Id1 as an initial factor in the BCa carcinogenic process and in the case of being confirmed Id1 could represent a target in BCa prophylaxis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gurney EP, Blank SV: Fortuitous detection of endocervical adenocarcinoma in situ: a report of 2 cases. J Reprod Med; 2009 Jul;54(7):451-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fortuitous detection of endocervical adenocarcinoma in situ: a report of 2 cases.
  • Biopsies revealed adenocarcinoma in situ, and cold-knife conization was performed.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Endometrial Neoplasms / pathology. Papanicolaou Test. Papillomavirus Infections / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691263.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chang MC, Nevadunsky NS, Viswanathan AN, Crum CP, Feltmate CM: Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol; 2010 Jan;29(1):88-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival.
  • Adenocarcinoma in situ (AIS) of the endocervix is typically confined to the cervix, but may be extensive.
  • We report 2 cases of extensive AIS-one with intraendometrial spread-that recurred after cone biopsy and were associated with ovarian metastases.
  • Both patients are currently disease-free and one has had no recurrence after a follow-up period of 145 months.
  • Extensive, recurring AIS is a rare variant that may be unique for its risk of coincident ovarian involvement.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma in Situ / pathology. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 May;29(3):298-300; author reply 300-1; discussion 300-2 [20407334.001]
  • [CommentIn] Int J Gynecol Pathol. 2011 Jan;30(1):62-3 [21131831.001]
  • (PMID = 19952931.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


20. Biscotti CV, Ray N: Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ. Diagn Cytopathol; 2010 Aug;38(8):551-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ.
  • Endometrium directly sampled from endocervical mucosal endometriosis can mimic endocervical adenocarcinoma in situ (AIS) in Papanicolaou (Pap) tests.
  • We analyzed a series of Pap tests to investigate the cellular features of mucosal endometriosis and to assess the utility of stroma and apoptotic bodies in the differential diagnosis with AIS.
  • Pap test samples from patients known to have endocervical mucosal endometriosis were compared with samples containing AIS.
  • By comparison, only one (8%) AIS case had endometrial-type stroma.
  • Seven (58%) AIS cases had apoptotic bodies and three (25%) had mitotic figures.
  • These lesional cells almost always include stroma, which is useful in the differential diagnosis with AIS.
  • We identified stroma significantly more often in endometriosis cases (92%) than in AIS cases (8%).
  • In the absence of stroma, AIS should be considered.
  • [MeSH-major] Carcinoma in Situ / pathology. Cervix Uteri / pathology. Endometriosis / pathology. Mucous Membrane / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods


21. Smedts F, Ramaekers FC, Hopman AH: The two faces of cervical adenocarcinoma in situ. Int J Gynecol Pathol; 2010 Jul;29(4):378-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The two faces of cervical adenocarcinoma in situ.
  • In order of frequency, cervical intraepithelial neoplasia (CIN), combined adenocarcinoma in situ (AIS)/CIN lesions, and solitary AIS are the most prevalent premalignant lesions of the uterine cervix.
  • As the morphologic distinction of these subtypes is not always straightforward, we performed an immunophenotyping analysis to establish distinguishing profiles for each of these squamous and glandular progenitor lesions of cervical carcinoma.
  • A series of 26 premalignant cervical lesions, comprising 13 cases of AIS, of which 7 represented solitary AIS and 6 were combined with CIN (combined AIS/CIN), as well as 13 solitary high-grade CIN lesions, were immunophenotypically analyzed using antibodies directed against p16, p63, bcl-2, and cytokeratins (CK) 5, 7, 8, 13, 17, 18, and 19.
  • Combined AIS/CIN lesions also expressed the full complement of markers in both the AIS and CIN compartments.
  • However, the expression of p63, bcl-2, CK5, and CK17 was lower in AIS compared with CIN.
  • The solitary AIS lesions could be subdivided into 2 subgroups, 1 expressing the full complement of markers and a second group in which no expression of p63, bcl-2, CK5, and a sporadically CK17 expression was observed.
  • We conclude that 2 phenotypically distinct types of AIS can be identified, that is, AIS with a reserve cell marker phenotype and AIS with an endocervical glandular phenotype.
  • These observations support the view that reserve cells are capable of bidirectional premalignant transformation, that is, into CIN and reserve cell-type AIS, as well as combined AIS/CIN.
  • The endocervical type of AIS is probably a result of the unidirectional transformation of progenitor cells within the glandular cell compartment.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567153.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


22. Kim JH, Park JY, Kim DY, Kim YM, Kim YT, Nam JH: The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. Eur J Obstet Gynecol Reprod Biol; 2009 Jul;145(1):100-3
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenocarcinoma in situ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix.
  • OBJECTIVES: To evaluate the occurrence of residual or recurrent disease after loop electrosurgical excisional procedure (LEEP) for adenocarcinoma in situ (AIS) of the uterine cervix.
  • STUDY DESIGN: Records of 78 patients with a histological diagnosis of AIS of uterine cervix on LEEP who were treated and followed at our center between 1992 and 2008 were, retrospectively, reviewed.
  • Of the 47 patients with negative margins, 30 underwent subsequent hysterectomy and residual AIS, including 1 invasive adenocarcinoma, was present in 17% (5/30) of patients.
  • Of the 31 patients with positive margins, 29 patients underwent subsequent hysterectomy and residual AIS, including 4 invasive adenocarcinomas, was present in 48% (14/29) of patients.
  • CONCLUSIONS: The incidence of residual disease in patients with negative margins after LEEP for AIS of the uterine cervix is low but not negligible.
  • However, positive resection margin carries a higher risk for residual AIS or occult invasive adenocarcinoma, warranting additional LEEP or hysterectomy in these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Electrosurgery / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428171.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 31
  •  go-up   go-down


23. Salani R, Puri I, Bristow RE: Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol; 2009 Feb;200(2):182.e1-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.
  • OBJECTIVE: We sought to determine the value of conization margin status in predicting residual and recurrent adenocarcinoma in situ (ACIS) of the cervix.
  • Metaanalysis with pooled Mantel-Haenszel odds ratio (OR) was used to compare the risk of residual and recurrent disease according to margin status.
  • RESULTS: A repeated excisional procedure was performed in 607 patients; a positive conization margin was associated with a significant increase in the risk of residual disease (OR, 4.01; 95% confidence interval [CI], 2.62-6.33; P < .001).
  • Invasive adenocarcinoma was more commonly associated with positive margins (5.2%) compared with negative margins (0.1%).
  • CONCLUSION: After conization for ACIS, patients with positive margins are significantly more likely to have residual or recurrent disease, whereas those with negative margins may be treated conservatively.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Conization. Neoplasm Recurrence, Local / epidemiology. Neoplasm, Residual / epidemiology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019325.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


24. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH). J Clin Oncol; 2009 May 20;27(15_suppl):5533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH).
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging.
  • We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • CONCLUSIONS: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dunton CJ: Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am; 2008 Dec;35(4):623-32; ix
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenocarcinoma in situ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of atypical glandular cells and adenocarcinoma in situ.
  • It is a challenge for the clinician to manage and follow this unusual cytologic finding properly.
  • It also discusses the diagnosis of associated endometrial lesions and the use of human papillomavirus DNA testing in the management of glandular lesions of the lower genital tract.
  • [MeSH-major] Adenocarcinoma / therapy. Cervical Intraepithelial Neoplasia / therapy. Pregnancy Complications, Neoplastic / therapy. Uterine Cervical Neoplasms / therapy


26. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Dalrymple C, Valmadre S, Cook A, Atkinson K, Carter J, Houghton CR, Russell P: Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):116-20
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome.
  • Eighty-two patients with adenocarcinoma in situ of the cervix managed at Royal Prince Alfred Hospital were reviewed and data were collected on those treated by cold knife cone biopsy (n= 38) and laser cone biopsy (n= 44).
  • Invasive disease was found in 24 patients, 16 of whom were managed conservatively with good outcome.
  • In those patients from both groups managed conservatively, there was only one recurrence, squamous preinvasive disease after 8 years.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Conization / methods. Laser Therapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506846.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Terada T: Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. Arch Gynecol Obstet; 2010 Mar;281(3):527-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman.
  • INTRODUCTION: Simultaneous occurrence of squamous cell carcinoma in situ (SIS) and adenocarcinoma in situ (AIS) is very rare in Japan.
  • CASE: The author reports a rare case of coexistence of SIS and AIS in a young Japanese woman.
  • Colposcopic examination revealed irregular lesions in the cervix, and a biopsy showed simultaneous SIS and AIS.
  • The SIS corresponded to cervical intraepithelial neoplasm3, HGSIL, or carcinoma in situ, and AIS was typical AIS.
  • The SIS showed in situ atypical cells without stratification and polarity.
  • The AIS showed tubular or cribriform apparent AIS of mixed endocervical and intestinal type.
  • Most of the areas of SIS and AIS were separated but the two were occasionally seen to merge when involving the glands.
  • The Ki-67 labeling was 82% in the SIS and 78% in the AIS.
  • CONCLUSION: The author reported a Japanese case of combined SIS and AIS, so far infrequently reported in Japanese woman.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology


29. Zafar N, Balazs L, Benstein BD: Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case. Diagn Cytopathol; 2008 Nov;36(11):823-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case.
  • At biopsy, the cervix contained synchronous squamous cell carcinoma in situ, secondarily involving endocervical glands, and neighboring adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831021.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Kruse AJ, Skaland I, Munk AC, Janssen E, Gudlaugsson E, Baak JP: Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. Hum Pathol; 2008 Apr;39(4):573-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ.
  • Clinically, it is important to distinguish cervical intraepithelial neoplasia grade 3 (CIN3) lesions with and without coexisting adenocarcinoma in situ (AIS), but endocervical curetting can be false negative.
  • The frequency of high-risk human papillomavirus genotypes in CIN3 patients with and without AIS differs.
  • CIN3 epithelial cell cycle regulator expression may reflect these differences and thereby indicate coexistent AIS.
  • G1 pathway epithelial cell cycle regulators (pRb, p53, cyclin D, p16) and Ki-67 were analyzed by quantitative immunohistochemistry in CIN3s with and without AIS.
  • CIN3s with coexistent AIS had a significantly lower percentage of pRb (P = .03)- and p53 (P = .03)-positive nuclei in the lower half of the epithelium than CIN3s without coexistent AIS.
  • None of the 10 cases with values of either pRb-positive nuclei 30% or greater or p53-positive nuclei 15% or greater in the lower half of the epithelium had coexistent AIS, contrasting 8 (24%) of the 33 cases with both low values of p53- and pRb-positive nuclei.
  • Combined low p53 and pRb expression in the lower half of the epithelium in punch biopsies is associated with coexistent AIS in the cone.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / complications. Retinoblastoma Protein / analysis. Tumor Suppressor Protein p53 / analysis. Uterine Cervical Neoplasms / diagnosis


31. Witkiewicz A, Lee KR, Brodsky G, Cviko A, Brodsky J, Crum CP: Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS. Am J Surg Pathol; 2005 Dec;29(12):1609-14
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS.
  • Although established histologic criteria for the diagnosis of endocervical adenocarcinoma in situ (AIS) have been published, some lesions are not readily classified or present with more subtle degrees of epithelial atypia.
  • Lesions confined to the surface mucosa may be particularly challenging, possibly because they represent early disease.
  • Twelve cases of superficial AIS (SAIS) confined to the surface mucosa or crypt openings culled from the in-house and consultation practices were examined histologically, immunostained for MIB-1 and p16, and analyzed (when possible) for HPV nucleic acids by DNA-DNA in situ hybridization (INFORM).
  • The mean age was 26.7 years for SAIS versus 37.0 years for 42 consecutive cases of conventional AIS from the same practice (P < 0.001).
  • SAIS is an early variant of AIS that 1) occurs at a younger mean age, 2) exhibits variable atypia, and 3) arises adjacent to morphologically normal columnar epithelium.
  • Diffuse p16 expression and integrated HPV pattern are identical to that seen in more extensive forms of the disease.
  • Superficial AIS should be suspected in endocervical columnar epithelium with segmental nuclear hyperchromasia with mitotic activity, and confirmed by biomarker staining (p16 and Mib-1) if the pathologist is uncertain of the diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Apoptosis. Biopsy. Cell Nucleus / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Conization. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA Probes, HPV. DNA, Neoplasm / metabolism. DNA, Viral / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Ki-67 Antigen / analysis. Mitosis. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327433.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV; 0 / DNA, Neoplasm; 0 / DNA, Viral; 0 / Ki-67 Antigen
  •  go-up   go-down


32. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, Pelusi C, Syrjanen S, Syrjanen K, Pelusi G: Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol; 2007 Jul;106(1):170-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix.
  • OBJECTIVE: The present study assessed (i) the clinical outcome of patients with conservatively treated cervical adenocarcinoma in situ (AIS), (ii) the accuracy of diagnosing AIS by cytology, colposcopy and histology, as well as (iii) the performance of cervical cytology and HPV testing in detection of residual or recurrent disease after conservatively treated AIS.
  • METHODS: A series of 42 consecutive women (mean age 40.5 years; range 27-63 years) underwent conservative (cone) treatment of AIS and were prospectively followed up for a mean of 40 months (median 42 months), using colposcopy, PAP smear, biopsy and HPV testing (with hybrid capture II) repeated at 6-month intervals.
  • Twenty four patients (57.1%) had AIS as a pure lesions and 18 combined with squamous cell lesion (four had invasive SCC).
  • Persistent or recurrent disease was observed in 17 (40.4%) cases, 19% in patients with free margins, and 65% among those with involved margins on the first conization.
  • In four patients, an adenocarcinoma (AdCa) stage IA1 was diagnosed during the follow-up.
  • HPV testing significantly predicted disease persistence/clearance with OR 12.6 (95% CI 1.18-133.89), while the predictive power of PAP smear did not reach statistical significance at any of the follow-up visits.
  • CONCLUSIONS: These results suggest that HR-HPV test in conjunction with cytology offers clear advantages over single cytology in monitoring the women conservatively treated for cervical AIS.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Carcinoma in Situ. Conization. DNA, Viral / analysis. Female. Follow-Up Studies. Humans. Middle Aged. Papanicolaou Test. Papillomaviridae / genetics. Predictive Value of Tests. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481701.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


33. Rabelo-Santos SH, Villa LL, Derchain SF, Ferreira S, Sarian LO, Angelo-Andrade LA, do Amaral Westin MC, Zeferino LC: Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. Int J Gynecol Pathol; 2006 Oct;25(4):393-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear.
  • Human papillomavirus (HPV) genotypes cannot fully explain the histological diagnosis of women with glandular abnormalities detected by cervical smear.
  • Thus, this study was designed to analyze the distribution of HPV-16 and HPV-18 variants in women referred because of atypical glandular cells and adenocarcinoma in situ in their cervical smears and its association with histological results.
  • Among the 15 cases associated with the European variant, 14 (93%) presented squamous neoplasia and 1 (7%) invasive adenocarcinoma.
  • Asian-American HPV-16 variants were significantly associated with histological diagnosis of glandular neoplasia alone (odds ratio, 9.3 [1.4-60.2]) or associated with squamous neoplasia (odds ratio, 18.7 [1.5-232.3]).
  • Adenocarcinomas were detected in 4 of 6 HPV-18-positive cases, being 2 cases had the European variant, 1 had the Asian Amerindian variant, and 1 had the African variant.
  • [MeSH-major] Adenocarcinoma / virology. Cervical Intraepithelial Neoplasia / virology. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Uterine Cervical Neoplasms / virology. Uterine Cervicitis / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990718.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


34. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Watkins C, Duffield E, Armour A, Mok T: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol; 2009 May 20;27(15_suppl):8006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8006^ Background: IPASS demonstrated overall superiority of first-line G vs C/P for progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma NSCLC in Asia.
  • EGFR gene-copy number was evaluable in 406 pts by fluorescence in situ hybridization (FISH; 61% FISH +).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962786.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Dubé V, Lickrish GM, MacNeill KN, Colgan TJ: Villoglandular adenocarcinoma in situ of intestinal type of the hymen: de novo origin from squamous mucosa? J Low Genit Tract Dis; 2006 Jul;10(3):156-60
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular adenocarcinoma in situ of intestinal type of the hymen: de novo origin from squamous mucosa?
  • Adenocarcinomas of the lower genital tract are rare diseases, and most of them arise from the Bartholin glands.
  • Villoglandular adenocarcinoma of intestinal type is a very uncommon neoplasm of unknown origin with only few cases described on the vulva and in the vagina.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma in Situ / diagnosis. Hymen / pathology. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Vaginal Discharge / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829755.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


36. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • Usual-type AIS was always diffusely CK7 positive, typically diffusely CEA and p16 positive, and always CK20 negative.
  • All usual cervical adenocarcinomas were diffusely CK7 and p16 positive, and all were immunoreactive with CEA.
  • Intestinal-type AIS was diffusely CK7 positive (all cases) and typically CK20 negative and diffusely CEA and p16 positive.
  • In addition, usual-type AIS adjacent to intestinal type was CDX2 positive in 13 of 21 cases.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • The foci of signet ring cells in the 2 primary cervical adenocarcinomas were diffusely CK7 and p16 positive and negative with CK20 and CDX2.
  • Colorectal adenocarcinomas involving the cervix were typically diffusely positive with CK20, CEA, and CDX2; negative with CK7; and negative or focally positive with p16.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • CDX2 positivity in usual-type AIS adjacent to intestinal type and in occasional cases of pure usual-type AIS may be a reflection of early intestinal differentiation before this is morphologically apparent.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


37. Rabelo-Santos SH, Derchain SF, Villa LL, Costa MC, Sarian LO, do Amaral Westin MC, Kornegay J, Zeferino LC: Human papillomavirus-specific genotypes in cervical lesions of women referred for smears with atypical glandular cells or adenocarcinoma in situ. Int J Gynecol Pathol; 2009 May;28(3):272-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-specific genotypes in cervical lesions of women referred for smears with atypical glandular cells or adenocarcinoma in situ.
  • Of the 160 women included, 111 were diagnosed with atypical glandular cells, 35 had both atypical glandular cells and high-grade squamous intraepithelial lesions, whereas 14 women had AIS, in 1 case associated with high-grade squamous intraepithelial lesions.
  • Histologic diagnoses were either cervical intraepithelial neoplasia or invasive carcinoma in 75 (58%) women, and negative for neoplasia in 54 (42%).
  • In women with cervical intraepithelial neoplasia 2 or 3, 11 different HPV genotypes were found, whereas in those who had invasive glandular or invasive carcinoma HPV 16 and HPV 18 were found predominantly.
  • [MeSH-major] Adenocarcinoma / virology. Cervical Intraepithelial Neoplasia / virology. Papillomaviridae / genetics. Papillomavirus Infections / genetics. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620946.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Sidoruk AA, Novik VI, Urmancheeva AF: [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri]. Vopr Onkol; 2009;55(6):733-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri].
  • Clinical and morphological investigation involved 57 patients with adenocarcinoma in situ of the cervix uteri (poorly-differentiated (precancerous) cell carcinoma in situ (PAIS)--30; adenocarcinoma in situ (AIS)--27).
  • Predictions for PAIS histotype were confirmed in 83%, cytological findings--78%; AIS--52% and 58%, respectively.
  • Accuracy for PAIS and AIS biopsy was 52% and 32%, respectively.
  • However, our procedure failed to detect malignant process in 17.5% (PAIS--6 cases and AIS--4) which was established by use of smears (Feulgen).
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Vaginal Smears


39. Miller B, Dunn J, Dalrymple J, Krivak TC: Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol; 2005 Nov;99(2):489-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ.
  • BACKGROUND: Traditionally, hysterectomy is considered definitive therapy for cervical adenocarcinoma in situ (AIS) in women beyond childbearing.
  • CASE: A 45-year-old gravida 2, para 2 patient presented with cervical dysplasia and on pathology review of the large loop excision procedure cervical adenocarcinoma in situ was diagnosed.
  • Final pathology revealed adenocarcinoma in situ with negative margins.
  • A CT-guided biopsy of the mass was consistent with invasive adenocarcinoma of the endocervical type.
  • CONCLUSION: This case depicts another example of the unpredictable nature of cervical AIS.
  • Despite undergoing definitive surgery, a residual focus of disease may remain leading to invasive adenocarcinoma.
  • Close follow-up is required of all patients diagnosed with AIS because the disease is poorly understood.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Pelvic Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054200.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC: Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol; 2007 Aug;197(2):195.e1-7; discussion 195.e7-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ: the predictive value of conization margin status.
  • OBJECTIVE: We evaluated the impact of conization margin status on outcomes of patients diagnosed with cervical adenocarcinoma in situ.
  • STUDY DESIGN: A retrospective chart review identified patients at a University hospital from 1988-2006 with adenocarcinoma in situ (AIS) on conization.
  • Of patients with positive margins, 55% (12/22) were diagnosed with residual or recurrent disease, including 3 patients diagnosed with adenocarcinoma on hysterectomy.
  • Thirteen percent of patients with negative conization margins (6/46) were diagnosed with residual or recurrent disease, including 2 patients diagnosed with adenocarcinoma during follow-up.
  • CONCLUSIONS: Even with negative conization margins, women still face a risk of residual, recurrent, or invasive disease.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Cervix Uteri / pathology. Conization. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689647.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Kietpeerakool C, Srisomboon J, Prompittayarat W, Kanjanavaha P, Peuwsai R, Dheerakul C: Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization? Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):522-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization?
  • This study was undertaken to determine the effectiveness of the Papanicolaou (Pap) smear, colposcopically-directed biopsy (CDB), and endocervical curettage (ECC) in preconization detection of adenocarcinoma in situ (AIS) of the uterine cervix.
  • Women, whose cervical conization specimens contained adenocarcinoma in situ without any associated invasive lesion at Chiang Mai University Hospital between March 1998 and March 2006, were reviewed.
  • Glandular abnormality was detected by Pap smears in 22 women (43.1%).
  • In total, glandular abnormality was suspected in 31 women (60.8%) preoperatively.
  • According to the histological type of AIS, glandular abnormality suspected from preoperative evaluation was noted in 20 women (70.4%) who had pure AIS.
  • Among women with mixed AIS/HSIL, only 12 women (50.0%) had preoperative evaluation suggesting glandular abnormality.
  • These data demonstrate that the sensitivity of combining Pap smear, CDB and/or ECC in detecting glandular lesions before conization containing AIS appears to be suboptimal.
  • Further study concerning the improvement of detecting AIS before conization is warranted to select the most appropriate diagnostic conization method for such lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Conization. Uterine Cervical Neoplasms / diagnosis


42. Little L, Stewart CJ: Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Mod Pathol; 2010 Apr;23(4):611-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It may be difficult to distinguish reactive glandular lesions from adenocarcinoma in situ of the uterine cervix, and although several immunohistochemical markers have established value in this diagnostic setting, none is completely reliable.
  • Therefore, we investigated cyclin D1 staining in a series of 64 cervical biopsy specimens including examples of normal and reactive endocervical epithelium, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesions, and invasive adenocarcinoma.
  • Thirteen specimens also included a component of high-grade cervical squamous intraepithelial neoplasia.
  • In contrast, most cases of adenocarcinoma in situ were completely negative and, therefore, cyclin D1 staining distinguished benign from neoplastic epithelial cells.
  • Although focal cyclin D1 expression was observed in 5/19 cases of adenocarcinoma in situ, the staining was associated with more marked cytological atypia precluding confusion with a reactive process.
  • The invasive adenocarcinomas were mainly negative for cyclin D1.
  • In conclusion, cyclin D1 can be included within an immunohistochemical panel to aid in the distinction between reactive cervical glandular lesions and adenocarcinoma in situ.
  • The localized distribution of staining within invasive lesions suggests that cyclin D1 up-regulation has a specific role during the progression of some endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin D1 / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062011.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136601-57-5 / Cyclin D1
  •  go-up   go-down


43. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ, Corless CL: Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol; 2009 May 20;27(15_suppl):4513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).
  • 9 PTS (10%) had in-situ cancer or T1N0M0.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Lacour RA, Garner EI, Molpus KL, Ashfaq R, Schorge JO: Management of cervical adenocarcinoma in situ during pregnancy. Am J Obstet Gynecol; 2005 May;192(5):1449-51
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cervical adenocarcinoma in situ during pregnancy.
  • OBJECTIVE: Adenocarcinoma in situ (AIS) is a precursor of invasive disease that is being more frequently diagnosed during the reproductive years.
  • The purpose of this study was to review our collective experience managing cervical AIS during pregnancy.
  • STUDY DESIGN: Retrospective medical record review of all women diagnosed with AIS during pregnancy from 1995 to 2004 at 3 academic institutions.
  • Five who received a diagnosis in the early second trimester underwent uncomplicated cold knife conization (CKC) at 14 to 19 weeks' gestation.
  • One patient undergoing postpartum CKC required radical hysterectomy for stage IB1 cervical adenocarcinoma.
  • CONCLUSION: Management of cervical AIS during pregnancy by early second trimester CKC is safe for mother and fetus.
  • [MeSH-major] Adenocarcinoma / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


45. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol; 2007 Oct;197(4):340-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.
  • The management of low-grade cervical intraepithelial neoplasia (CIN) grade 1 has been modified significantly.
  • Moreover, management recommendations for women with biopsy-confirmed adenocarcinoma in situ are now included.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Cervical Intraepithelial Neoplasia / surgery. Uterine Cervical Neoplasms / surgery


46. Ooi A, Zen Y, Ninomiya I, Tajiri R, Suzuki S, Kobayashi H, Imoto I, Dobashi Y: Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. Pathol Int; 2010 Jun;60(6):466-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus.
  • We examined 11 cases of carcinoma arising from Barrett's esophagus consisting of two adenocarcinomas in situ (ACIS), two intramucosal adenocarcinomas, and seven overt invasive adenocarcinomas.
  • Overexpression of p53 (implying a mutation of the p53 gene), ERBB2, and EGFR was measured by immunohistochemistry, and gene amplification of ERBB2 and EGFR was measured by fluorescence in situ hybridization (FISH).
  • In all cases of ACIS and the intramucosal adenocarcinomas, almost all cancer cells overexpressed p53, however the populations overexpressing ERBB2 and EGFR varied in different cases: in one ACIS, ERBB2 was coexpressed in all the cancer cells, in the other ACIS and one intramucosal adenocarcinoma, ERBB2 was overexpressed in about 50% and only 10% of the p53-positive cells respectively.
  • EGFR was co-expressed in 20% in the other intramucosal adenocarcinoma.
  • These gene amplifications, however, were not found in the seven invasive adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Carcinoma in Situ / genetics. Gene Amplification. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Esophagus / metabolism. Esophagus / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mucous Membrane / metabolism. Mucous Membrane / pathology. Neoplasm Invasiveness / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518902.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


47. Park KJ, Soslow RA, Sonoda Y, Barakat RR, Abu-Rustum NR: Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. Gynecol Oncol; 2008 Sep;110(3):316-23
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system.
  • OBJECTIVE: To analyze the incidence of diagnostic discrepancy between frozen-section and final diagnosis of the endocervical margin at time of radical trachelectomy and to apply an objective scoring system to non-invasive endocervical glandular atypia to determine its utility in distinguishing benign from malignant lesions.
  • METHODS: Histologic slides from 19 cases of radical trachelectomy performed for invasive endocervical adenocarcinoma were evaluated for correlation between the frozen and permanent sections of the endocervical margin.
  • An objective scoring system for grading non-invasive endocervical glandular lesions proposed by Ioffe et al. was also applied to the frozen and permanent section slides and compared to the final diagnosis.
  • RESULTS: There was 84% concordance between the frozen-section and final diagnosis using histology alone, vs. 95% concordance using the Ioffe scoring system.
  • One trachelectomy was converted to completion hysterectomy for what was presumed to be adenocarcinoma in situ at the margin, which in retrospect, was a benign lesion and was correctly classified using the Ioffe system.
  • Most of the discrepancies were due to misinterpretation of tubal metaplasia, tubo-endometrioid metaplasia, and atypical tubal metaplasia as adenocarcinoma in situ.
  • CONCLUSION: Benign mimics of endocervical adenocarcinoma in situ can be difficult to distinguish from malignant lesions, especially during frozen-section evaluation of the trachelectomy.
  • Correctly diagnosing the margin status intraoperatively has great clinical impact and the application of an objective scoring system, like that proposed by Ioffe et al., can increase diagnostic accuracy when applied to frozen-section slides and better correlates with final diagnosis when compared to histology alone.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Mar;13(3):261-74 [10757337.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):198-205 [12090586.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):1-4 [9891235.001]
  • [Cites] Am J Clin Pathol. 1996 Apr;105(4):403-10 [8604682.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):209-16 [8600071.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 1995 May;103(5):618-23 [7741110.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):452-60 [12657929.001]
  • [Cites] Int J Gynecol Pathol. 1992;11(2):89-95 [1582750.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):71-5 [17197900.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):176-80 [9071723.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jul;117(7):734-5 [8323440.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):170-5 [15084846.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):610-5 [15378361.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):971-6 [16876235.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(2):122-8 [2332270.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] Semin Diagn Pathol. 1991 Nov;8(4):234-49 [1759058.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1491-6 [9855586.001]
  • (PMID = 18635252.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS809092; NLM/ PMC4996344
  •  go-up   go-down


48. Stewart CJ, Little L: Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. Pathology; 2010 Apr;42(3):217-23
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-two cervical biopsy specimens including normal endocervical epithelium, tubo-endometrioid metaplasia, adenocarcinoma in situ, stratified mucin producing intraepithelial lesions (SMILE), and invasive adenocarcinomas were stained immunohistochemically for vimentin and for p16 protein, Ki-67 and bcl-2.
  • Twelve cases also included areas of high grade cervical intraepithelial neoplasia (CIN).
  • Usually adenocarcinoma in situ was completely negative and therefore vimentin staining sharply distinguished the benign and neoplastic epithelial elements.
  • Most invasive adenocarcinomas were not stained but focal vimentin immunoreactivity was observed in 7/18 cases, and was restricted to small glands and infiltrating cell clusters at the deep (advancing) tumour margin.
  • CONCLUSIONS: Normal endocervical cells often exhibit vimentin staining, and this is increased in reactive and metaplastic situations, whereas adenocarcinoma in situ is usually completely negative.
  • The localised re-expression of vimentin at the deep margin of some endocervical adenocarcinomas may be relevant to the process of tumour progression and invasion in these cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / metabolism. Vimentin / biosynthesis
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350213.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin
  •  go-up   go-down


49. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073612.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


50. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


51. Chen YY, Yi CH, Chen CL, Huang SC, Hsu YH: Hemorrhagic cholecystitis after anticoagulation therapy. Am J Med Sci; 2010 Oct;340(4):338-9
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemorrhagic cholecystitis is a rare and potentially fatal complication of biliary tract disease.
  • Laparoscopic cholecystectomy was performed with the histopathology report disclosing adenocarcinoma in situ.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Aged. Angina, Unstable / drug therapy. Aspirin / adverse effects. Female. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / diagnosis. Heparin / adverse effects. Humans

  • Genetic Alliance. consumer health - Cholecystitis.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601855.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 9005-49-6 / Heparin; R16CO5Y76E / Aspirin
  •  go-up   go-down


52. Austin RM, Onisko A, Druzdzel MJ: The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool. Arch Pathol Lab Med; 2010 May;134(5):744-50
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To create a unique Pittsburgh Cervical Cancer Screening Model (PCCSM) that quantifies risk for histopathologic cervical precancer (cervical intraepithelial neoplasia [CIN] 2, CIN3, and adenocarcinoma in situ) and cervical cancer in an environment predominantly using newer screening technologies.
  • RESULTS: The PCCSM compares risk quantitatively over time for histopathologically verifiable CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients for each current cytology result category and for each HPV result.
  • For each current cytology result, HPV test results affect risk; however, the degree of cytologic abnormality remains the largest positive predictor of risk.
  • Prior history also alters the CIN2, CIN3, adenocarcinoma in situ, and cervical cancer risk for patients with common current cytology and HPV test results.
  • The PCCSM can also generate negative risk projections, estimating the likelihood of the absence of histopathologic CIN2, CIN3, adenocarcinoma in situ, and cervical cancer in screened patients.
  • CONCLUSIONS: The PCCSM is a dynamic Bayesian network that computes quantitative cervical disease risk estimates for patients undergoing cervical screening.
  • Continuously updatable with current system data, the PCCSM provides a new tool to monitor cervical disease risk in the evolving postvaccination era.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Early Detection of Cancer / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Papanicolaou Test. Papillomavirus Infections / diagnosis. Risk Assessment. Risk Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441506.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis; 2007 Oct;11(4):223-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.
  • OBJECTIVE: To provide updated consensus guidelines for the management of women with cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS).
  • Moreover, management recommendations for women with biopsy-confirmed AIS are now included.
  • CONCLUSION: Updated evidenced-based guidelines have been developed for the management of women with CIN or AIS.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma in Situ / therapy. Cervical Intraepithelial Neoplasia / therapy. Electrosurgery. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Colposcopy. Disease Progression. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Regression, Spontaneous. Pregnancy. Pregnancy Complications, Neoplastic / therapy. Retreatment. Risk Factors


54. Sanati S, Huettner P, Ylagan LR: Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol; 2010 Jan;29(1):79-87
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine low-grade squamous intraepithelial lesion, 35 high-grade squamous intraepithelial lesion, 23 squamous metaplasia, and 14 adenocarcinoma in situ specimens were retrieved from our hospital files.
  • ProExC had sensitivity, specificity, and positive and negative predictive value of 89%, 100%, 100%, and 82%, respectively, for distinguishing high-grade squamous intraepithelial lesion from squamous metaplasia, and 93%, 100%, 100%, and 98%, respectively, for distinguishing adenocarcinoma in situ from reactive benign endocervix.
  • ProExC may eventually be used in conjunction with morphologic and human papillomavirus evaluation for better classification of indeterminate cervical lesions in Papanicolaou smears.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Immunoenzyme Techniques. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952938.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


55. Fujii T, Nakamura M, Kameyama K, Saito M, Nishio H, Ohno A, Hirao N, Iwata T, Tsukazaki K, Aoki D: Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system. Int J Gynecol Cancer; 2010 May;20(4):605-10
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system.
  • INTRODUCTION: Although the colposcopic features of cervical glandular disease and cervical adenocarcinoma are not widely well known, unique microvascular patterns are reportedly useful for identifying such diseases.
  • METHODS: Twenty-one patients with adenocarcinoma in situ or early invasive adenocarcinomas were examined using digital NBI colposcopy, and the photo records were compared with those of conventional colposcopy.
  • The vascular pattern was depicted in 86% (18/21) of glandular disease cases.
  • CONCLUSIONS: Digital NBI colposcopy was useful for identifying early cervical adenocarcinoma as well as adenocarcinoma in situ.
  • This system yields cervical glandular disease-related colposcopic findings that may be useful for both clinical and educational purposes.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Adenosquamous / diagnosis. Colposcopy. Diagnostic Imaging. Uterine Cervical Neoplasms / diagnosis


56. Ueda Y, Miyatake T, Okazawa M, Kimura T, Miyake T, Fujiwara K, Yoshino K, Nakashima R, Fujita M, Enomoto T: Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. Am J Clin Pathol; 2008 Sep;130(3):389-400
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HPV was in a mixed integrated-episomal form in a monoclonal GD, an adenocarcinoma in situ, and an adenocarcinoma.
  • These results imply that the concurrent glandular and squamous lesions are formed separately, whereas adenosquamous carcinoma is more likely to be a combination tumor of monoclonal origin, and that integration of HPV has an important role in the progression from polyclonal GD through monoclonal expansion to adenocarcinoma in situ and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Cervix Uteri / pathology. Cervix Uteri / virology. Endometrial Neoplasms / virology. Papillomavirus Infections / pathology
  • [MeSH-minor] Antibodies, Viral / analysis. Cervical Intraepithelial Neoplasia / immunology. Cervical Intraepithelial Neoplasia / pathology. Female. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Humans. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701412.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


57. Mittal K, Sebenik M, Irwin C, Yan Z, Popiolek D, Curtin J, Palazzo J: Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy. Mod Pathol; 2009 Jan;22(1):37-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy.
  • The distinction of complex atypical endometrial hyperplasia from endometrial adenocarcinoma is often problematic.
  • Foci of back-to-back arrangement of glands or foci of cribriform arrangement of glands smaller than 2.1 mm in diameter are considered insufficient for the diagnosis of endometrial adenocarcinoma by some authors, and sufficient to be diagnosed as endometrial adenocarcinoma by other authors.
  • We refer to these foci as endometrial adenocarcinoma in situ.
  • In this study, we evaluated findings in subsequent hysterectomy in complex atypical endometrial hyperplasia patients with and without adenocarcinoma in situ.
  • Follow-up findings, including the presence or absence of endometrial adenocarcinoma in the hysterectomy specimen, the grade of the carcinoma and the depth of myometrial invasion were analyzed.
  • Of the total 87 patients with complex atypical endometrial hyperplasia, 33 patients had adenocarcinoma in situ and 54 lacked adenocarcinoma in situ.
  • Of 33 patients 22 (66%) with adenocarcinoma in situ had endometrial adenocarcinoma on subsequent hysterectomy vs 13 of 54 (24%) patients without adenocarcinoma in situ (P=0.0001).
  • Myoinvasive endometrial adenocarcinoma was present in 20 of 33 (61%) patients with adenocarcinoma in situ vs 8 of the 54 (15%) patients without adenocarcinoma in situ (P< or =0.0001).
  • The depth of myometrial invasion in cases with myoinvasion was 24.5+19.4% in patients with adenocarcinoma in situ and 12.8+8.5% in patients without adenocarcinoma in situ (P=0.05).
  • Among patients younger than age of 50, 5 of the 7 (71%) with adenocarcinoma in situ had myoinvasive carcinoma vs 2 of the 13 (15%) without adenocarcinoma in situ (P=0.02).
  • The likelihood of finding endometrial adenocarcinoma in subsequent hysterectomy in patients with complex atypical endometrial hyperplasia is significantly increased if adenocarcinoma in situ is present in prior endometrial sampling.
  • Endometrial adenocarcinomas in patients with adenocarcinoma in situ are far more frequently myoinvasive, and invade to a greater depth than endometrial adenocarcinomas seen in patients without adenocarcinoma in situ.
  • Use of adenocarcinoma in situ terminology could lead to improved management of patients with complex atypical endometrial hyperplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19116629.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • In this immunohistochemical study the utility of the ProEx C reagent in distinguishing AIS and AC from a variety of non-neoplastic glandular lesions was examined.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • The median and distribution of prevalence of immunohistochemical staining for AIS was different from all benign mimics, but the intensity of staining for AIS did overlap with some mimics as it was not significantly different from endometriosis, microglandular hyperplasia, and reactive endocervix.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


59. Flannelly G: The management of women with abnormal cervical cytology in pregnancy. Best Pract Res Clin Obstet Gynaecol; 2010 Feb;24(1):51-60
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The emphasis should be on diagnosis and confirmation of cervical precancer (Cervical intraepithelial neoplasia (CIN) or Adenocarcinoma in situ (AIS), thus excluding invasive cancer).
  • The management of women with invasive cancer diagnosed during pregnancy depends on the gestation at diagnosis and requires careful assessment and multidisciplinary planning.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Precancerous Conditions / surgery. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Colposcopy. Evidence-Based Medicine. Female. Humans. Hysterectomy / methods. Pregnancy. Survival Analysis. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805007.001).
  • [ISSN] 1532-1932
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


60. Noguchi M: Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. Cancer Metastasis Rev; 2010 Mar;29(1):15-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications.
  • Stepwise progression of pulmonary adenocarcinoma is described from the viewpoint of both pathology and molecular biology.
  • Pulmonary adenocarcinoma develops to invasive carcinoma through atypical adenomatous hyperplasia, adenocarcinoma in situ and minimally invasive adenocarcinoma.
  • On the other hand, in terms of molecular biology, p16 gene inactivation, EGFR mutation and KRAS mutation are early events, and tumors progress to invasive adenocarcinoma as a result of p53 mutation, loss of various chromosomes and other genetic abnormalities.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology
  • [MeSH-minor] Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Humans. Neoplasm Invasiveness. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20108111.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 29
  •  go-up   go-down


61. Roberts JM, Thurloe JK, Biro C, Hyne SG, Williams KE, Bowditch RC: Follow-up of cytologic predictions of endocervical glandular abnormalities: histologic outcomes in 123 cases. J Low Genit Tract Dis; 2005 Apr;9(2):71-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We obtained histologic follow-up for 100% of 67 cytologic predictions of adenocarcinoma in situ (AIS) and 82% of 39 predictions of possible AIS (?AIS) made over a 4-year period (1999-2002) and for 25% of 105 atypical endocervical cells (AEC) predictions over a 12-month period (2000).
  • RESULTS: PPVs for predictions of AIS and ?AIS for high-grade lesions overall were 91% and 75% (p = .032), respectively, and those for high-grade glandular lesions were 88% and 72% (p = .046), respectively.
  • CONCLUSION: Cytology can accurately predict AIS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Uterine Cervical Neoplasms / diagnosis


62. De Caro G, Pagano N, Malesci A, Hervoso C, Danese S, Romeo F, Delconte G, Repici A: Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e32-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 72-year-old woman underwent gastric endoscopic mucosal resection with a cap-fitted endoscope for an adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / adverse effects. Neoplasm Recurrence, Local / surgery. Stomach Diseases / etiology. Stomach Neoplasms / surgery. Surgical Instruments
  • [MeSH-minor] Aged. Cicatrix / pathology. Cicatrix / surgery. Female. Humans. Iatrogenic Disease. Stomach / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620913.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Kjaer SK, Andersen ES, Djursing H, Hansen T, Jørgensen JJ, Nilas L, Ottesen BS, Petersen LK, Thomsen SG, Toftager-Larsen K: [Quadrivalent HPV 6/11/16/18 vaccine]. Ugeskr Laeger; 2007 Nov 12;169(46):3971-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vaccine prevented 98% of CIN2, CIN3 and adenocarcinoma in situ related to HPV 16 or HPV 18 among women not previously exposed to these types, and 44% among all women (i.e. both those with and without previous infection).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • (PMID = 18078651.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


64. Hatami M, Del Priore G, Chudnoff SG, Goldberg GL: Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. Arch Iran Med; 2006 Oct;9(4):413-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy.
  • A 32-year-old female was diagnosed by loop electrosurgical excision procedure with adenocarcinoma in situ and a focus suspicious for positive lympho-vascular invasion.
  • [MeSH-major] Adenocarcinoma / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061618.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


65. Dekker AH: Fostering acceptance of human papillomavirus vaccines. J Am Osteopath Assoc; 2006 Mar;106(3 Suppl 1):S14-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivalent prophylactic human papillomavirus (HPV) vaccines currently in the late stages of clinical testing are safe, immunogenic, and efficacious; and phase 3 tests of a quadrivalent vaccine show that it is 100% effective at preventing HPV types 16 and 18-associated cervical intraepithelial neoplasia grades 2 and 3, adenocarcinoma in situ, and cervical cancer through 2 years of postvaccination follow-up.
  • These vaccines promise to reduce the burden of HPV-related disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729556.001).
  • [ISSN] 0098-6151
  • [Journal-full-title] The Journal of the American Osteopathic Association
  • [ISO-abbreviation] J Am Osteopath Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines; 0 / Viral Vaccines
  • [Number-of-references] 18
  •  go-up   go-down


66. Park KJ, Soslow RA: Current concepts in cervical pathology. Arch Pathol Lab Med; 2009 May;133(5):729-38
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The correct diagnosis and reporting of cervical in situ and invasive carcinoma are essential for the appropriate clinical management of patients with human papillomavirus-associated disease.
  • OBJECTIVES: To review common mistakes made in the diagnosis of cervical dysplasia and invasive carcinoma, describe variants and benign mimics of high-grade squamous intraepithelial lesion and adenocarcinoma in situ, and discuss available ancillary studies that can be useful in making the distinctions as well as to review important factors related to prognosis that should be included in the pathology report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415947.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 74
  •  go-up   go-down


67. Zimmerman RK: HPV vaccine and its recommendations, 2007. J Fam Pract; 2007 Feb;56(2 Suppl Vaccines):S1-5, C1
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vaccine is 95% to 100% efficacious against cervical intraepithelial neoplasia and adenocarcinoma in situ and 99% efficacious against genital warts caused by serotypes in the vaccine.
  • [MeSH-major] Carcinoma in Situ / prevention & control. Disease Outbreaks / prevention & control. Papillomavirus Infections / epidemiology. Papillomavirus Vaccines / administration & dosage. Sexually Transmitted Diseases, Viral / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270106.001).
  • [ISSN] 1533-7294
  • [Journal-full-title] The Journal of family practice
  • [ISO-abbreviation] J Fam Pract
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / P60MD000207; United States / PHS HHS / / U66/CCU723241
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 28
  •  go-up   go-down


68. Nucci MR, Crum CP: Redefining early cervical neoplasia: recent progress. Adv Anat Pathol; 2007 Jan;14(1):1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evolution in our understanding of preinvasive glandular neoplasia is also summarized, with particular attention to so-called superficial (or early) adenocarcinoma in situ.
  • In addition, practical issues in the diagnosis and management of squamous epithelial lesions, particularly the recognition of nonconventional variants and the application of biomarkers, are discussed.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


69. Odashiro AN, Odashiro DN, Nguyen GK: Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology. Diagn Cytopathol; 2006 Feb;34(2):119-23
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology.
  • Three histologically confirmed minimal deviation endometrioid adenocarcinomas (MDEA) of the uterine cervix with cytologic evaluation by cervical scraping were reviewed.
  • The cytologic manifestations of those three cervical MDEAs overlapped, to some extents, with those of a cervical adenocarcinoma in situ and with those of a well-differentiated endometrial adenocarcinoma invading the cervix.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16511847.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Zen Y, Fujii T, Itatsu K, Nakamura K, Konishi F, Masuda S, Mitsui T, Asada Y, Miura S, Miyayama S, Uehara T, Katsuyama T, Ohta T, Minato H, Nakanuma Y: Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol; 2006 Sep;19(9):1243-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary cystic tumors, which are also called biliary cystadenoma and cystadenocarcinoma, are thought to be a heterogeneous disease entity, and some of them are known to show a luminal communication to the bile duct.
  • Biliary cystic tumors examined in this study were histologically adenoma (one case), adenocarcinoma in situ (six cases), and adenocarcinoma associated with microinvasive mucinous carcinoma (two cases).
  • One case of adenocarcinoma in situ also had the adenoma component (adenocarcinoma in adenoma).
  • Intraepithelial neoplasm was observed within non-dilated adjacent bile ducts, suggesting a direct luminal communication between the cystic tumors and the bile duct.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Cystadenocarcinoma / pathology. Cystadenoma / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma in Situ. Disease-Free Survival. Female. Fluorescent Antibody Technique, Indirect. Homeodomain Proteins / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucin-1 / metabolism. Mucin-2. Mucins / secretion. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 2 June 2006.
  • (PMID = 16741522.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


71. Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N: Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body. Dig Surg; 2008;25(1):46-51
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 10 patients with intraductal papillary mucinous neoplasms, 3 patients had minimally invasive adenocarcinoma, and 3 had adenocarcinoma in situ.
  • A medial pancreatectomy was converted to a distal pancreatectomy in 1 patient with adenocarcinoma in situ.
  • Three patients with islet cell tumor and 1 patient with solid pseudopapillary tumor had no malignant disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Islet Cell / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292661.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


72. Pavlakis K, Messini I, Athanassiadou S, Kyrodimou E, Pandazopoulou A, Vrekoussis T, Stathopoulos EN: Endocervical glandular lesions: a diagnostic approach combining a semi-quantitative scoring method to the expression of CEA, MIB-1 and p16. Gynecol Oncol; 2006 Dec;103(3):971-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The hematoxylin and eosin-stained sections of 95 cervical biopsies were examined by 4 different observers and were grouped into three categories, benign, dysplasia and adenocarcinoma in situ, depending on the degree of nuclear stratification, nuclear atypia and the number of mitosis and apoptotic figures.
  • This scoring system discriminates effectively (Kruskal-Wallis, p<0.001) between the three categories (benign, endocervical glandular dysplasia and adenocarcinoma in situ).
  • Nevertheless, the proportion of cases that were classified similarly to the prestudy diagnosis was higher when the combined score was used.
  • [MeSH-major] Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876235.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


73. Bucher P, Pugin F, Morel P: Single-port access laparoscopic radical left colectomy in humans. Dis Colon Rectum; 2009 Oct;52(10):1797-801
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Umbilical single-port access (embryonic natural orifice transluminal endoscopic surgery) left colectomy was performed in a patient with sigmoid colon adenocarcinoma in situ.
  • Final diagnosis revealed an adenocarcinoma in situ.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2009 Oct;52(10):1801-2 [19966618.001]
  • (PMID = 19966617.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1).
  • In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].
  • Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative.
  • PAX2 expression in the 2 positive endocervical adenocarcinomas was patchy and weak.
  • Most (11 of 15) stage II endometrial endometrioid adenocarcinomas lacked PAX2 expression but 1 of 10 grade 1 tumors and 3 of 5 grade 2 tumors did express PAX2.
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry / methods. Neoplasm Staging. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


75. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • Of the 37 adenocarcinomas, all were negative for PSA and PSAP (0/37; 0%).
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Acid Phosphatase. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Membrane Proteins / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Protein Tyrosine Phosphatases / biosynthesis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


76. Dahlström LA, Ylitalo N, Sundström K, Palmgren J, Ploner A, Eloranta S, Sanjeevi CB, Andersson S, Rohan T, Dillner J, Adami HO, Sparén P: Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer; 2010 Oct 15;127(8):1923-30
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of human papillomavirus and risk of cervical adenocarcinoma.
  • However, causality inference is dependent on prospective evidence showing that exposure predicts risk for future disease.
  • Such evidence is available for squamous cell carcinoma, but not for cervical adenocarcinoma.
  • Baseline smears from women who developed adenocarcinoma during follow-up (118 women with in situ disease and 164 with invasive disease) and their individually matched controls (1,434 smears) were analyzed for HPV using PCR.
  • Conditional logistic regression was used to estimate odds ratios (OR) of future adenocarcinoma with 95% confidence intervals (CI).
  • Being positive for HPV 16 in the first cytologically normal smear was associated with increased risks for both future adenocarcinoma in situ (OR: 11.0, 95% CI: 2.6-46.8) and invasive adenocarcinoma (OR: 16.0, 95% CI: 3.8-66.7), compared to being negative for HPV 16.
  • Similarly, an HPV 18 positive smear was associated with increased risks for adenocarcinoma in situ (OR: 26.0, 95% CI: 3.5-192) and invasive adenocarcinoma (OR: 28.0, 95% CI: 3.8-206), compared to an HPV 18 negative smear.
  • Being positive for HPV 16/18 in 2 subsequent smears was associated with an infinite risk of both in situ and invasive adenocarcinoma.
  • In conclusion, infections with HPV 16 and 18 are detectable up to at least 14 years before diagnosis of cervical adenocarcinoma.
  • Our data provide prospective evidence that the association of HPV 16/18 with cervical adenocarcinoma is strong and causal.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1301-4 [16265348.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):429-35 [10760834.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1025-31 [16803480.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):885-91 [17131323.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):622-9 [18445828.001]
  • [Cites] J Clin Microbiol. 2009 Mar;47(3):541-6 [19144817.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):525-9 [19449379.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6027-32 [11085523.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Biometrics. 1988 Jun;44(2):355-67 [3390504.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):498-505 [7640239.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Aug;17(4):221-9 [8526946.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):755-63 [9328198.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):159-66 [10487628.001]
  • [Cites] Cancer Detect Prev. 2004;28(6):461-4 [15582270.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):171-5 [16404371.001]
  • (PMID = 20473898.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093378-01A1; United States / NCI NIH HHS / CA / R01 CA093378-01A1; United States / NCI NIH HHS / CA / R01 CA111720-01; United States / NCI NIH HHS / CA / CA111720-02; United States / NCI NIH HHS / CA / CA111720-01; United States / NCI NIH HHS / CA / 1R01CA93378-01A1; United States / NCI NIH HHS / CA / R01CA111720-02; United States / NCI NIH HHS / CA / R01 CA111720-02; United States / NCI NIH HHS / CA / R01 CA093378; United States / NCI NIH HHS / CA / R01CA111720-01; United States / NCI NIH HHS / CA / 5R01CA111720-03; United States / NCI NIH HHS / CA / R01 CA111720-03; United States / NCI NIH HHS / CA / R01 CA111720; United States / NCI NIH HHS / CA / CA111720-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS207185; NLM/ PMC2930102
  •  go-up   go-down


77. Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM: Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol; 2005 Mar;29(3):281-94
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms.
  • The vast majority of endocervical adenocarcinomas are high-risk human papillomavirus (HPV)-related neoplasms, characterized by p16 expression and frequent loss of hormone receptor expression, which infrequently metastasize to the ovaries.
  • We report 10 cases of endocervical adenocarcinomas with ovarian metastases in which the ovarian tumors simulated primary ovarian surface epithelial neoplasms.
  • The ovarian metastases presented concurrently with the primary endocervical tumors in 5 cases, subsequent to the endocervical tumors in 3 cases, and prior to diagnosis of the endocervical tumors in 2 cases.
  • Adenocarcinoma in situ was identified in all tumors.
  • Two of the minimally invasive endocervical tumors were initially interpreted as adenocarcinoma in situ and not recognized as unequivocally invasive even when evaluated in conjunction with the histologically identical ovarian tumors.
  • HPV DNA detection in the ovarian tumors of 2 patients without known cervical disease led to discovery of occult cervical adenocarcinomas in those patients.
  • Endocervical adenocarcinomas, including some qualifying as microinvasive, can metastasize to the ovaries and simulate primary ovarian surface epithelial neoplasms.
  • The presence of HPV DNA in these ovarian tumors confirms that they are metastatic endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Middle Aged. Neoplasm Metastasis / pathology. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2005 Dec;29(12):1686-7; author reply 1687-9 [16327448.001]
  • (PMID = 15725796.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


78. Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, Kurman RJ: Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol; 2008 Dec;32(12):1835-53
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms.
  • Most endocervical adenocarcinomas ( approximately 90%) are high-risk human papillomavirus (HPV)-related neoplasms, with the remainder being unrelated to HPV; both types infrequently metastasize to the ovaries.
  • In 11 cases, the cervical tumors were more limited; these included 5 tumors comprised predominantly of adenocarcinoma in situ with small foci of superficial invasion ("microinvasive carcinomas") diagnosed before the ovarian metastases (3 mo to 7 y) and 6 tumors comprised of extensive adenocarcinoma in situ lacking unequivocally recognizable stromal invasion diagnosed before (9 mo to 7 y, n=4), concurrently with (n=1), or subsequent to (n=1) the ovarian metastases.
  • Endocervical adenocarcinomas, including microinvasive forms and some not recognizably invasive, have the potential to metastasize to the ovaries; extension into the lower uterine segment/corpus endometrium may be a risk factor, with retrograde uterine/transtubal spread as a possible mechanism.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology. Polymerase Chain Reaction. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813124.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


79. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM: Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol; 2009 Jun;33(6):914-24
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
  • Determining the primary site of a uterine adenocarcinoma can be problematic in hysterectomy specimens due to the overlapping morphology of endocervical adenocarcinomas and endometrial carcinomas, particularly when both the corpus (usually lower uterine segment) and endocervix are involved and precursor lesions are lacking or difficult to distinguish from intramucosal spread of carcinoma from one site to the other.
  • Both preferential extension of endocervical adenocarcinomas into the endometrium (rather than deep cervical stroma) and myometrial invasion derived from the endometrial component are rarely encountered; to our knowledge, these unusual patterns of spread have not been detailed in prior reports.
  • Clinicopathologic features of 10 endocervical adenocarcinomas (9 pure, 1 adenosquamous) with prominent endometrial or endomyometrial involvement were evaluated.
  • Six cases had limited amounts of tumor in the cervix proper, with depths of invasion no greater than 5 mm in 4 and only adenocarcinoma in situ in 2.
  • Five tumors were originally diagnosed as primary endometrial carcinoma with either cervical extension or concurrent endocervical adenocarcinoma in situ.
  • These ancillary techniques are useful for clarifying the origin of uterine adenocarcinomas when morphologic features and tumor location are equivocal.
  • These cases illustrate that dominant uterine corpus involvement (endometrial or endomyometrial) by primary endocervical adenocarcinoma can lead to misclassification as primary endometrial adenocarcinoma with cervical extension (Fédération Internationale de Gynécologie et d'Obstétrique stage II), especially when endometrial extension of endocervical adenocarcinoma simulates complex atypical hyperplasia.
  • A subset of misclassified endocervical adenocarcinomas may account for some HPV-positive uterine carcinomas reported as primary endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Receptors, Steroid / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / metabolism. Endometrium / pathology. Endometrium / virology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomaviridae. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295407.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Steroid
  •  go-up   go-down


80. Dedecker F, Graesslin O, Bonneau S, Quéreux C: [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases]. Gynecol Obstet Fertil; 2008 Jun;36(6):616-22
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases].
  • [Transliterated title] Persistance et récidive des adénocarcinomes in situ après traitement: à propos d'une série rétrospective multicentrique de 121 cas.
  • OBJECTIVE: The aim of this study is to assess the results of conservative management of adenocarcinoma in situ (AIS) of the uterine cervix.
  • General characteristics of population, diagnosis circumstances, treatment, histology and evolution were studied.
  • DISCUSSION AND CONCLUSION: Conservative surgery for patients with AIS could be considered in young patients but several conditions should be respected: careful follow-up after conservative treatment; cold knife conization; length of cone specimen greater than 25 mm and negative margins.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Neoplasm Recurrence, Local / prevention & control. Papillomavirus Infections / surgery. Uterine Cervical Neoplasms / surgery


81. Daniel A, Barreth D, Schepansky A, Johnson G, Capstick V, Faught W: Histologic and clinical significance of atypical glandular cells on pap smears. Int J Gynaecol Obstet; 2005 Dec;91(3):238-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 197(45.2%) patients had a clinically significant diagnosis including 40 with adenocarcinoma in situ (AIS) of the cervix and 48 with endometrial cancer.
  • CONCLUSION: AGC on a Pap smear is frequently associated with a clinically significant diagnosis.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Genital Diseases, Female / pathology. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202416.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Graesslin O, Dedecker F, Collinet P, Jouve E, Urbaniack D, Leroy JL, Boulanger JC, Quéreux C: [Management of in situ cervical adenocarcinoma]. Gynecol Obstet Fertil; 2006 Dec;34(12):1178-84
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of in situ cervical adenocarcinoma].
  • [Transliterated title] Prise en charge de l'adénocarcinome in situ du col utérin.
  • The management of adenocarcinoma in situ of the cervix (ACIS) is difficult because it is often diagnosed in younger women who may wish to preserve their potential of fertility.
  • We report a complete review of the literature on this subject where conservative attitude appears possible but is associated with recurrence risk (5 to 10%) and invasive disease (2%).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Colposcopy / methods. Reproduction. Uterine Cervical Neoplasms / surgery


83. Tawfik El-Mansi M, Williams AR: Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. Int J Gynecol Cancer; 2006 May-Jun;16(3):1225-33
Biospecimen Research Database. Biospecimen Research Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system.
  • We used a large series of cervical adenocarcinomas to investigate TMA technology in assessment of immunohistochemical staining.
  • A TMA was constructed using 273 archival paraffin blocks from 139 patients with 119 invasive and 20 adenocarcinoma in situ and 16 normal controls.
  • Our results suggest that TMAs can be successfully used for immunohistochemical studies of cervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Microarray Analysis / methods. Tissue Array Analysis / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Female. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Models, Biological. Molecular Diagnostic Techniques. Neoplasm Invasiveness / diagnosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803510.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


84. Belsley NA, Tambouret RH, Misdraji J, Muzikansky A, Russell DK, Wilbur DC: Cytologic features of endocervical glandular lesions: comparison of SurePath, ThinPrep, and conventional smear specimen preparations. Diagn Cytopathol; 2008 Apr;36(4):232-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conventional, ThinPrep and SurePath specimens with either endocervical adenocarcinoma in situ or invasive endocervical adenocarcinoma were evaluated for architectural and cytological features previously described for endocervical neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18335553.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Sameshima S, Tomozawa S, Koketsu S, Okada T, Miyato H, Iijima M, Kojima M, Kaji T: Intramucosal adenocarcinoma of the ileum originated 40 years after ileosigmoidostomy. World J Surg Oncol; 2009;7:41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramucosal adenocarcinoma of the ileum originated 40 years after ileosigmoidostomy.
  • BACKGROUND: Small bowel adenocarcinomas (SBAs) are rare carcinomas.
  • A mucosal biopsy specimen showed adenocarcinoma histopathologically.
  • Histological examination revealed a well differentiated intramucosal adenocarcinoma (adenocarcinoma in situ).
  • Immunohistological staining demonstrated the overexpression of p53 protein in the adenocarcinoma.
  • CONCLUSION: Adenocarcinoma of the ileum at such an early stage is a very rare event.
  • [MeSH-major] Adenocarcinoma / etiology. Appendicitis / surgery. Colon, Sigmoid / surgery. Ileal Neoplasms / etiology. Ileostomy / adverse effects. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2003 May;18(3):276-8 [12785331.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Arch Pathol Lab Med. 1982 Jun;106(6):308-9 [6896439.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Dis Colon Rectum. 1985 Jun;28(6):383-8 [4006632.001]
  • [Cites] Ann Surg. 1989 Jun;209(6):764-73 [2543338.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Clin Pract Suppl. 2005 Apr;(147):106-8 [15875642.001]
  • [Cites] Endoscopy. 2005 Aug;37(8):755-9 [16032496.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Int J Colorectal Dis. 2006 Jul;21(5):478-82 [16365680.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1647-54 [16863573.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):474-80 [17676397.001]
  • [Cites] Dis Colon Rectum. 2009 Mar;52(3):538-41 [19333060.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):101-4 [10813131.001]
  • [Cites] Int J Colorectal Dis. 2001 Apr;16(2):126-30 [11355319.001]
  • [Cites] World J Surg. 2002 Mar;26(3):390-6 [11865380.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1423-7 [12818291.001]
  • (PMID = 19379525.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2676285
  •  go-up   go-down


86. Kennedy CM, Peterson LB, Galask RP: Erosive vulvar lichen planus: a cohort at risk for cancer? J Reprod Med; 2008 Oct;53(10):781-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the occurrence of cancer, including vulvovaginal squamous cell carcinoma (SCC), among women after diagnosis of erosive vulvar lichen planus (LP).
  • RESULTS: A diagnosis of cancer was made in 5 women after diagnosis of erosive vulvar LP.
  • The remaining 2 cancer diagnoses included cervical adenocarcinoma in situ and rectal adenocarcinoma.

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004404.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 1K23 HD045769
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


87. Cox JT: History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol; 2009 Jul;45 Suppl 1:S3-S12
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, cross sectional studies and large randomized trials have provided clinical validation for high-risk HPV testing in triage of atypical squamous cells of undetermined significance (ASC-US), in postcolposcopy management of women referred for ASC-US, atypical squamous cells "cannot rule out high grade" (ASC-H), atypical glandular cells "not otherwise specified" (AGC NOS) and low grade squamous intraepithelial lesion (LSIL) and not found to have cervical intraepithelial neoplasia (CIN) 2+ or adenocarcinoma in situ (AIS) at initial colposcopy, in post-treatment of CIN 2+ surveillance, and in cotesting with the Papanicolaou (Pap) test of women age 30 and over.
  • [MeSH-major] Mass Screening / history. Mass Screening / methods. Papanicolaou Test. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / prevention & control. Vaginal Smears / history. Vaginal Smears / methods


88. Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR: Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer; 2006 May-Jun;16(3):1025-31
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.
  • Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical adenocarcinoma (and its precursors) in Scottish patients.
  • We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in situ, and 16 cases of normal glandular epithelium.
  • No significant relation between infecting HPV type (16 or 18) and subtypes of disease (within the invasive category and between the preinvasive and the invasive categories) was noted.
  • Our findings support that HPV-16, along with HPV-18, are likely to play a significant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for the reduction of adenocarcinoma and associated glandular precursors.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / etiology. Cervical Intraepithelial Neoplasia / virology. DNA Probes, HPV. Female. Genotype. Humans. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / virology. Polymerase Chain Reaction / methods. Polymorphism, Restriction Fragment Length. Prevalence. Scotland / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803480.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


89. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y: Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol; 2007 Jul;128(1):100-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
  • Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains unclear whether bronchioloalveolar carcinoma (BAC) components and/or subtypes affect these associations.
  • We examined 141 non-small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12 of the K-ras gene using loop-hybrid mobility shift assays, a highly sensitive polymerase chain reaction-based method.
  • Adenocarcinomas were subdivided into subtypes with a nonmucinous or mucinous BAC component and those without BAC components.
  • In NSCLCs, EGFR mutations were detected in 75 cases (53.2%) and were significantly associated with adenocarcinoma, female sex, and never smoking.
  • Among adenocarcinomas, nonmucinous and mucinous BAC components were significantly associated with EGFR and K-ras gene mutations, respectively.
  • Because EGFR mutations were detected even in most pure nonmucinous BACs, ie, lung adenocarcinoma in situ, EGFR mutation is considered a critical event in the pathogenesis of nonmucinous BAC tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580276.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


90. Nomura T, Yamashita K, Miyashita M, Tajiri T: [Argon plasma coagulation in Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1458-62
Hazardous Substances Data Bank. Argon, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, it has been reported that Barrett's esophagus and Barrett's adenocarcinoma in situ could be successfully managed by APC.
  • The aims of this treatment are to prevent the developing of adenocarcinoma and to promote the restitution of normal squamous epithelium.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Combined Modality Therapy. Enzyme Inhibitors / therapeutic use. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / surgery. Humans. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101240.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Proton Pump Inhibitors; 67XQY1V3KH / Argon
  • [Number-of-references] 15
  •  go-up   go-down


91. Omori M, Hashi A, Ishii Y, Yuminamochi T, Nara M, Kondo T, Hirata S, Katoh R, Hoshi K: Clinical impact of preoperative screening for gastric mucin secretion in cervical discharge by HIK1083-labeled latex agglutination test. Am J Clin Pathol; 2008 Oct;130(4):585-94
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glandular lesions with a gastric phenotype were identified histologically in all 26 cases positive for the HIK1083 latex test, such as minimal deviation adenocarcinoma, lobular endocervical glandular hyperplasia (LEGH), and pyloric gland metaplasia, but not in negative cases.
  • In 2 cases of LEGH, adenocarcinoma in situ was identified.
  • Screening of gastric mucin in cervical discharge may facilitate preoperative detection of some early cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Gastric Mucins / analysis. Latex Fixation Tests. Uterine Cervical Neoplasms / diagnosis. Vaginal Discharge / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Mass Screening / methods. Middle Aged. Precancerous Conditions / diagnosis. Preoperative Care

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794052.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastric Mucins
  •  go-up   go-down


92. Kondo T, Hashi A, Murata S, Nakazawa T, Yuminamochi T, Nara M, Hoshi K, Katoh R: Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses. Mod Pathol; 2005 Sep;18(9):1199-210
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses.
  • We report on four cases of endocervical adenocarcinoma associated with lobular endocervical glandular hyperplasia using histochemical and immunohistochemical analyses.
  • Cytological examinations of the cervical smears revealed adenocarcinoma cells and benign-looking glandular cells with intracytoplasmic golden-yellow mucin in all cases.
  • From surgical specimens, three tumors were diagnosed as mucinous adenocarcinoma and one was adenocarcinoma in situ.
  • All adenocarcinomas were located proximally on the cervix, and did not involve the transformation zone.
  • Focal immunopositivity for pyloric mucin was also observed in three adenocarcinomas.
  • Either CEA or p53 were immunopositive in all adenocarcinomas and negative in the tissues of lobular endocervical glandular hyperplasia.
  • Histopathological features of the present cases suggest that some endocervical adenocarcinomas may originate from lobular endocervical glandular hyperplasia.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Hyperplasia / complications. Hyperplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Middle Aged. Mucins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761489.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


93. Zhao H, Davydova L, Mandich D, Cartun RW, Ligato S: S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol; 2007 Mar;127(3):374-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of S100A4 protein was observed in 8 invasive carcinomas (80%), 5 HGD/carcinoma in situ cases (83%), and 0 LGDs.
  • Mesothelin was expressed in 5 (50%) of 10 adenocarcinomas, 1 (17%) of 6 HGD/adenocarcinoma in situ cases, and 0 LGDs.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Epithelium / chemistry. Epithelium / pathology. GPI-Linked Proteins. Humans. Immunohistochemistry. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276942.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / S100 Proteins; 0 / mesothelin; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


94. Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E: Histologic implications of Pap smears classified as atypical glandular cells. J Reprod Med; 2005 Jul;50(7):539-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 64 were classified as AGC not otherwise specified (NOS) (56.6%), 48 AGC favor neoplasia (42.5%) and 1 (0.9%) adenocarcinoma in situ.
  • Significant abnormality was found in 30 women (26.5%).
  • Eleven percent of women with smears reported as AGC NOS and 45.8% of those with AGC favor neoplasia had significant abnormality.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Retrospective Studies. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


95. Frank JE: The colposcopic examination. J Midwifery Womens Health; 2008 Sep-Oct;53(5):447-52
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocervical sampling may accompany colposcopy, particularly in the evaluation of nonpregnant women with cytology results of atypical glandular cells and adenocarcinoma in situ.
  • [MeSH-minor] Adolescent. Biopsy. Female. Humans. Midwifery. Physical Examination. Postmenopause. Pregnancy. Uterine Cervical Diseases / diagnosis. Vaginal Diseases / diagnosis


96. Boyadzhieva M, Atanassova I, Dimitrova V, Zaharieva S, Tankova T, Grozeva G, Todorova K, Stoykova V, Kedikova S: [Our and foreign experience in surgical treatment of CIN III-cold knife conisation versus LLETZ]. Akush Ginekol (Sofiia); 2010;49(3):9-11
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive disease and recurrence were observed in 150 patients--50 of them having adenocarcinoma in situ.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / surgery. Conization / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cervix Uteri / pathology. Cervix Uteri / surgery. Female. Humans. Laser Therapy / instrumentation. Laser Therapy / methods. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734649.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


97. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y: Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol; 2007 Sep;20(9):967-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating epidermal growth factor receptor (EGFR) gene mutations are frequently detected in lung adenocarcinomas, especially adenocarcinomas with a nonmucinous bronchioloalveolar carcinoma component.
  • EGFR-mutated lung adenocarcinomas respond well to EGFR tyrosine kinase inhibitors.
  • We previously found that most (88%) pure nonmucinous bronchioloalveolar carcinomas (adenocarcinoma in situ) already harbor EGFR mutations, indicating that the mutations are an early genetic event in the pathogenesis.
  • We examined 54 atypical adenomatous hyperplasias, precursor lesions of lung adenocarcinomas, obtained from 28 Japanese patients for the hotspot mutations of EGFR exons 19 and 21 and K-ras codon 12.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenomatosis, Pulmonary / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group / genetics. Codon. DNA Mutational Analysis. Disease Progression. Exons. Female. Genes, ras. Humans. Hyperplasia. Japan. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618248.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


98. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Sireci AN, Crapanzano JP, Mansukhani M, Wright T, Babiac A, Erroll M, Vazquez M, Saqi A: Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. Diagn Cytopathol; 2010 Oct;38(10):705-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the study was to determine if the ThinPrep Imaging System (T1S) improves the positive predictive value (PPV) of atypical glandular cell (AGC) diagnosis for identifying HPV-related squamous and/or glandular lesions over manual screening (MS), and if human papilloma virus (HPV)-DNA testing improves the diagnostic yield.
  • MATERIALS AND METHODS: 85 ThinPrep cervical cytology specimens with a diagnosis of AGC by TIS (n = 51) and MS (n = 34) were retrieved.
  • In the MS group, more cases of glandular pathology were identified, however only three represented adenocarcinoma in-situ (AIS), and the remaining ten were endometrial carcinomas (EMCA).
  • Although the MS group harbored more glandular pathology, the differences in the detection of AIS were not statistically significant.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Precancerous Conditions / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Wiley-Liss, Inc.
  • (PMID = 20014311.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


100. Skórzewska K, Radowicki S, Matuszkiewicz-Rowinska J, Szlendak-Sauer K: Morphological changes in endometrium of hemodialyzed women of reproductive age. Gynecol Endocrinol; 2007 Sep;23(9):523-6
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial biopsy revealed one case of adenocarcinoma in situ.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943547.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down






Advertisement